By Thomas Dobrow
Integra Lifesciences Holdings Corp (NASDAQ
:IART)‘s stock had its “buy” rating reissued by equities researchers at Piper Jaffray in a research note issued on Thursday, ARN reports.
A number of other research analysts have also issued reports on the stock. Lake Street Capital lowered their target price on shares of Integra Lifesciences Holdings Corp from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Wednesday, August 26th. Zacks downgraded shares of Integra Lifesciences Holdings Corp from a “hold” rating to a “sell” rating in a report on Monday, August 24th. JPMorgan Chase & Co. raised shares of Integra Lifesciences Holdings Corp from a “neutral” rating to an “overweight” rating and set a $80.00 price objective on the stock in a research note on Friday, July 31st. Raymond James upgraded Integra Lifesciences Holdings Corp from a “market perform” rating to an “outperform” rating in a report on Wednesday, July 29th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $78.00 price objective (up previously from $67.00) on shares of Integra Lifesciences Holdings Corp in a research report on Monday, July 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $71.33.
